Denmark's Ministry of Economy has explicitly raised its 2026 GDP growth forecast, directly attributing this upward revision to the substantial revenue generated by Novo Nordisk's GLP-1 drug franchise, primarily Ozempic and Wegovy. This announcement is notable because it is rare for a national economy to adjust its GDP forecast based on the sales performance of a single company.
Novo Nordisk's global revenues represent a significant portion of Denmark's total national economic output, making the company's performance a material macroeconomic factor for Danish policymakers. The GLP-1 weight-loss and diabetes drug boom has redefined pharmaceutical industry revenue expectations, with Ozempic and Wegovy generating tens of billions in annual sales globally.
Novo Nordisk has grown from a significant Danish industrial company to one of Europe's largest corporations by market capitalization in just a few years. The company's Wegovy pill continues its strong uptake in the US, with total weekly prescriptions exceeding 265,000 as of mid-July. The Wegovy pill also launched in the UAE in June and the UK in July, with plans for additional launches in other markets. For 2026, Novo Nordisk adjusted its outlook, expecting adjusted sales growth to be 0% to -6% at constant exchange rates and adjusted operating profit growth also at 0% to -6% at constant exchange rates, an improvement driven by increased expectations for GLP-1 product sales.
